Genetic Technologies Ltd (GENE) Financials

Stock symbol GENE is outdated, potentially delisted? Maybe it is available on other exchange?

GENE Assets vs Liabilities

Date	Assets	Liabilities
Dec. 31, 2023	5.8 million	2.5 million
Sept. 30, 2023	?	?
June 30, 2023	9.9 million	2.5 million
March 31, 2023	10.0 million	2.5 million

GENE Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.

Date	Free Cash Flow	Stock based compensation
Dec. 31, 2023	-2.7 million	?
Sept. 30, 2023	-13498	?
June 30, 2023	-1.7 million	84074
March 31, 2023	-691256	85049

GENE Net Income

No data available :(

GENE Cash and Debt

Graph available only for paid members. Upgrade to see it.

Date	Cash	Debt	Capital Lease
Dec. 31, 2023	2.5 million	-	-
Sept. 30, 2023	-	-	-
June 30, 2023	5.2 million	-	353505
March 31, 2023	5.3 million	-	-

GENE Shares Outstanding

Graph available only for paid members. Upgrade to see it.

Date	Shares Outstanding
Dec. 31, 2023	78.6 million
Sept. 30, 2023	?
June 30, 2023	61.3 million
March 31, 2023	7.4 billion

GENE Expenses

Graph available only for paid members. Upgrade to see it.

Date	Capex	R&D	G&A	S&M
Dec. 31, 2023	4769	265542	-	-
Sept. 30, 2023	13498	-	-	-
June 30, 2023	7961	479560	189086	430296
March 31, 2023	671	242561	191279	435286

GENE Cost of Revenue

Graph available only for paid members. Upgrade to see it.

Date	Revenue	Cost of Revenue
Dec. 31, 2023	2.7 million	4.0 million
Sept. 30, 2023	-	-
June 30, 2023	3.0 million	3.8 million
March 31, 2023	1.8 million	734067

GENE

Price: $0.76

52 week price:

0.67

3.75

Earnings Per Share: -0.15 USD

P/E Ratio: -14.82

Exchange: NCM

Sector: Healthcare

Industry: Diagnostics & Research

Country: Australia

Volume: 666231

Ebitda: -5.8 million

Market Capitalization: 2.7 million

Links:

GENE on Yahoo Finance